

LABORATORY CORP OF AMERICA HOLDINGS
Form DEFA14A
April 06, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under §240.14a-12

Laboratory Corporation of America Holdings

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form DEFA14A

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

SUPPLEMENT TO PROXY STATEMENT

2018 ANNUAL MEETING OF SHAREHOLDERS

On March 30, 2018, Laboratory Corporation of America Holdings (the Company) filed a definitive proxy statement (the Proxy Statement) with the Securities and Exchange Commission relating to the Company's 2018 Annual Meeting of Shareholders to be held on May 10, 2018.

The Company has determined that while all components of total compensation shown in the Summary Compensation Table appearing on page 46 of the Proxy Statement are correct, there were computational errors in the Total column of the table with respect to several of the named executive officers. The Company has restated the Summary Compensation Table below to correct the errors in the Total column for David P. King for fiscal years 2016 and 2015 and for F. Samuel Eberts III and Glenn A. Eisenberg for fiscal year 2017. The information set forth below modifies and replaces the Summary Compensation Table set forth in the Proxy Statement.

Summary Compensation Table

The compensation paid, accrued or awarded during the years ended December 31, 2015, 2016 and 2017 to the Company's NEOs, which includes the Chief Executive Officer, the Chief Financial Officer, and the three other most highly compensated executive officers who were serving as executive officers as of December 31, 2017, is set forth below:

| NAME AND PRINCIPAL POSITION | YEAR | CHANGE IN PENSION VALUE AND NONQUALIFIED NON-EQUITY DEFERRED INCENTIVE COMPENSATION ALL OTHER | | | | | | TOTAL (\$) |
|-----------------------------------|------|--|---------------------------------|--------------------------------|---|---------------------------------|--|--------------|
| | | SALARY (\$) ⁽¹⁾ | STOCK OPTIONS ⁽²⁾ | STOCK AWARDS ⁽²⁾ | PLAN COMPENSATION (\$) ⁽³⁾ | EARNINGS (\$) ⁽⁴⁾ | OTHER COMPENSATION (\$) ⁽⁵⁾ | |
| DAVID P. KING | 2017 | \$1,150,000 | 1,581,820 | \$6,749,173 | \$1,960,367 | \$128,904 | \$75,990 | \$11,646,254 |
| | 2016 | \$1,133,333 | \$- | \$7,683,109 | \$1,785,419 | \$101,810 | \$149,826 | \$10,853,497 |
| Chief Executive Officer | 2015 | \$1,044,481 | \$- | \$7,878,178 | \$1,672,371 | \$- | \$31,384 | \$10,626,414 |
| F. SAMUEL EBERTS III | 2017 | \$502,125 | \$111,350 | \$475,810 | \$389,204 | \$35,457 | 14,155 | \$1,528,101 |
| | 2016 | \$486,875 | \$- | \$529,589 | \$303,833 | \$26,784 | 12,590 | \$1,359,671 |
| Senior Vice President | | | | | | | | |
| Chief Legal Officer | 2015 | \$444,807 | \$- | \$600,318 | \$236,929 | \$- | \$14,590 | \$1,296,644 |
| | 2017 | \$666,474 | \$373,349 | \$1,588,668 | \$746,219 | \$- | \$33,035 | \$3,407,745 |

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form DEFA14A

| | | | | | | | | |
|---------------------------|------|-----------|-----|-------------|-----------|-----|----------|-------------|
| GLENN A. EISENBERG | 2016 | \$653,438 | \$- | \$2,799,854 | \$679,626 | \$- | \$10,030 | \$4,142,948 |
| | 2015 | \$635,417 | \$- | \$2,110,929 | \$676,912 | \$- | \$22,565 | \$3,445,823 |

Executive Vice
President

Chief Financial
Officer

GARY M. HUFF

Executive Vice

| | | | | | | | | |
|-------------------------------|------|-----------|-----|-------------|-----------|----------|----------|-------------|
| President, Chief Executive | 2017 | \$525,082 | \$- | \$2,964,735 | \$708,267 | \$48,451 | \$18,121 | \$4,264,656 |
|-------------------------------|------|-----------|-----|-------------|-----------|----------|----------|-------------|

Officer of LabCorp
Diagnostics

JOHN D. RATLIFF

Executive Vice
President, Chief

| | | | | | | | | |
|--|------|-----------|-----------|-------------|-----------|-----|----------|-------------|
| | 2017 | \$659,750 | \$697,573 | \$2,978,743 | \$648,415 | \$- | \$13,035 | \$4,997,516 |
|--|------|-----------|-----------|-------------|-----------|-----|----------|-------------|

Executive Officer
of Covance Drug

Development

The footnotes to the Summary Compensation Table set forth in the Proxy Statement are accurate and remain unchanged, and the foregoing table should be read in conjunction with the footnotes.

Except as specifically revised by the information contained herein, this supplement does not revise or update any of the other information set forth in the Proxy Statement. This supplement should be read in conjunction with the Proxy Statement. From and after the date of this supplement, any references to the Proxy Statement are to the Proxy Statement as supplemented hereby.

Shareholders who have already properly executed a proxy card or voted by telephone, by internet or by signing, dating and returning their proxy cards and who would like to change their vote may revoke their proxy before it is voted at the 2018 Annual Meeting of Shareholders by: (i) entering new instructions on either the telephone or Internet voting system before 11:59 p.m. Eastern Daylight Time on Wednesday, May 9, 2018; (ii) sending a new proxy card with a later date than the previously submitted proxy card, which new proxy card must be received before the polls close at the 2018 Annual Meeting on Thursday, May 10, 2018; or (iii) giving written notice of such revocation to the Corporate Secretary of the Company, as described in the Proxy Statement, which written notice must be received before the 2018 Annual Meeting begins on Thursday, May 10, 2018.

2 LABORATORY CORPORATION OF AMERICA HOLDINGS Supplement to Proxy Statement